Prana Biotechnology (ASX:PBT) has appointed movement disorder expert Professor Ira Shoulson to its board as a non-executive director. Shoulson is a professor of neurology, pharmacology and human science at Georgetown University in Washington DC. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) CEO Geoffrey Kempler said Shoulson’s experience will serve the company well as it prepares to meet with regulators to help determine the next stages in the development of drug candidate PBT2 in Huntington disease. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) weekly performance is -3.57%. On last trading day company shares ended up $1.62. Analysts mean target price for the company is $4.00. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) distance from 50-day simple moving average (SMA50) is -66.02%.
GSK will assign to Pernix the Product Development and Commercialization Agreement (“PDC Agreement”) between GSK and POZEN, Inc. (NASDAQ:POZN). POZEN and Pernix will amend the PDC Agreement to facilitate further development of Treximet. In addition, Pernix will release restrictions on POZEN’s right to develop and commercialize additional dosage forms of sumatriptan/naproxen combinations outside of the United States. POZEN Inc. (NASDAQ:POZN) shares fell -3.05% in last trading session and ended the day on $8.27. POZN return on assets is -13.60%. POZEN Inc. (NASDAQ:POZN) quarterly performance is 4.29%.
Nomura analyst M. Ian Somaiya is telling clients to buy Incyte Genomics, Inc. (NASDAQ: INCY) and Pharmacyclics, Inc. (NASDAQ: PCYC) following ASCO abstracts and into the meeting. Pharmacyclics, Inc. (NASDAQ:PCYC) shares moved down -1.98% in last trading session and was closed at $98.02, while trading in range of $96.46 – $99.48. Pharmacyclics, Inc. (NASDAQ:PCYC) year to date (YTD) performance is -7.34%.
Shares of Lannett Company Inc (NYSE:LCI) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,230,298 shares, an increase of 49.2% from the March 31st total of 824,464 shares, American Banking & Market News reports. Based on an average trading volume of 631,768 shares, the short-interest ratio is presently 1.9 days. Currently, 5.1% of the shares of the stock are sold short. Lannett Company, Inc. (NYSE:LCI) ended the last trading day at $36.62. Company weekly volatility is calculated as 4.11% and price to cash ratio as 12.30. Lannett Company, Inc. (NYSE:LCI) showed a positive weekly performance of 2.06%.
Endo International PLC (NASDAQ:ENDP), one of a half dozen U.S. drugmakers that recently took Irish addresses to save on taxes, said it plans to spend $60 million to pay personal tax bills incurred by top executives in connection with the switch,” Bloomberg reports.Endo International PLC (NASDAQ:ENDP) net profit margin is -22.70% and weekly performance is 5.06%. On last trading day company shares ended up $71.41. Analysts mean target price for the company is $71.50. Endo International PLC (NASDAQ:ENDP) distance from 50-day simple moving average (SMA50) is 7.73%.